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Human 20 ,50-oligoadenylate synthetase 3 (OAS3) exerts antiviral effect against alphaviruses including
Chikungunya virus (CHIKV) by inhibiting viral RNA accumulation. Here, we identiﬁed a CHIKV variant
exhibiting a remarkable resistance to the antiviral action of OAS3 in human epithelial HeLa cells. Using
a molecular clone of CHIKV with Renilla luciferase inserted as a reporter gene in the non-structural
region, we demonstrated that a single glutamine-to-lysine amino acid change at position 166 of the
envelope E2 glycoprotein restores CHIKV replication in OAS3 expressing HeLa cells. Viral entry assays
showed that CHIKV with a lysine at position E2-166 was more efﬁcient at entering the replicative
pathway. The E2-E166K substitution promotes a greater efﬁciency of CHIKV replication in human
myoblasts leading to severe apoptosis through a more robust activation of the PKR pathway. These
observations provide a new insight into the role of E2 into the pathogenicity of CHIKV in human cells.
& 2012 Elsevier Inc. All rights reserved.Introduction
Chikungunya virus (CHIKV) is an arthropod-borne virus of the
Alphavirus genus within the Togaviridae family. In 2005, CHIKV
reemerged in Eastern Africa from where it spreads to several
islands in the Indian Ocean and later on to India and South East
Asia causing a major epidemic with millions of infected people.
In Europe, the increased number of imported cases and the local
outbreaks of CHIKV observed in Italy in 2007 and in France in
2010 have raised concern whether CHIKV may become a serious
problem in temperate regions including Europe (Angelini et al.,
2007; Grandadam et al., 2011). In humans, acute CHIKV infection
is characterized by high fever, rash, headache, nausea, and severe
pain in muscle and joints with the latter symptoms persisting in
some patients for months or even years. (Borgherini et al., 2007,
2008; Robinson, 1955).
CHIKV, like other alphaviruses, is a small lipid enveloped virus
with a positive-sense single-stranded 11.5 kb RNA genome.
Together with the capsid protein, the genomic RNA forms the
icosahedral nucleocapsid at the core of the virion. The nucleocapsidll rights reserved.
res Flavivirus-Hoˆtes, Institut
e.
espres).is surrounded by a host-derived lipid membrane with heterodimers
of the envelope proteins, E1 and E2, embedded within. The E1–E2
heterodimer is responsible for viral entry through receptor-
mediated endocytosis with E2 binding cell surface receptors and
E1 facilitating membrane fusion. The acidic environment within the
endosome leads to dissociation of the E1–E2 heterodimer and a
conformational rearrangement of E1 that triggers fusion of viral and
endosomal membranes thus releasing the viral genome into the
cytoplasm. The 50 two-thirds of the genome are directly translated
into the non-structural polyprotein precursor which is cleaved by
itself to produce the non-structural proteins 1 to 4 (nsP1 to 4).
Together with cellular co-factors, the nsPs form the viral replication
complex that synthesizes ﬁrst negative-sense and secondly posi-
tive-sense genomic RNA. Besides the full-length positive-sense
genomic RNA, a smaller positive-sense subgenomic 26S RNA
corresponding to approximately 30 one-third of the genome is also
being synthesized. The structural polyprotein precursor is trans-
lated from the subgenomic 26S RNA and is later cleaved into the
individual structural proteins: capsid, the two major envelope
proteins E1 and E2 and two smaller peptides E3 and 6 K (Grifﬁn,
2007; Schwartz and Albert, 2010; Solignat et al., 2009; Strauss and
Strauss, 1994).
At the early stages of alphavirus life cycle, virus replication
leads to a marked shutoff of mRNA translation which is mediated
by activation of the RNA dependent protein kinase (PKR) pathway
Fig. 1. CHIKV-OAS3R shows resistance towards OAS3. In (A), HeLa.Tet-Off/OAS3
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(dsRNA) molecules, a byproduct of alphaviral replication, PKR
becomes activated through auto-phosphorylation. Once active,
PKR phosphorylates eukaryotic initiation factor 2a (eIF2a) which
in turn renders eIF2a inactive and blocks initiation of translation.
However, alphaviruses have developed strategies to evade block-
age of PKR-mediated inhibition of translation. Indeed, the sub-
genomic RNA contains stem loop structure that allows initiation
of translation without requirement of eIF2a (McInerney et al.,
2005; Ventoso et al., 2006). At the late stages of alphavirus life
cycle, shutoff of mRNA translation is followed by induction of
apoptosis and cell death (Krejbich-Trotot et al., 2011; Sourisseau
et al., 2007).
Alphaviruses are highly sensitive to the antiviral activity of
type I interferon (IFN) and several IFN-stimulated genes (ISG)
including ISG15, ISG20, P56, ZAP, Viperin, and 20,50-oligoadenylate
synthetases (OAS) exert antiviral activity against alphaviruses
(Brehin et al., 2009; Lenschow et al., 2007; MacDonald et al.,
2007; Schilte et al., 2010; Zhang et al., 2007). The OAS proteins are
a family of ISGs which are produced as latent enzymes and are
activated by binding to dsRNA. The interaction of OAS with dsRNA
leads to formation of the catalytically active OAS-RNA complex
and triggers the antiviral activity of OAS. The active OAS-RNA
complex polymerizes ATP into 20,50-linked oligoadenylates ran-
ging from dimers up to 30-mers. The 20,50-linked oligoadenylates
then binds a latent endoribonuclease, RNase L, triggering the
formation of catalytically active dimeric RNase L. This leads to
degradation of single stranded RNA, and subsequently to a
decrease in protein synthesis thereby inhibiting viral replication
(Hovanessian and Justesen, 2007; Kristiansen et al., 2011).
We have previously reported that the large form of human OAS
(OAS3) exerts antiviral effect against CHIKV in human epithelial
cells (Brehin et al., 2009). In the present study, we identiﬁed a
CHIKV variant exhibiting a remarkable resistance towards the
antiviral activity of OAS3 through an enhancement of viral RNA
replication. We showed that a single amino acid change in the
envelope E2 glycoprotein allows the rescue of viral growth in OAS3
expressing HeLa cells in acting on the early stages of viral life cycle.cells were infected with CHIKV-OAS3R or CHIKV-06.49 at different MOIs and virus
progeny production was determined at 24 h p.i. In (B), HeLa.Tet-Off or HeLa.Tet-
Off/OAS3 cells were infected with CHIKV-OAS3R or CHIKV-P10 at 1 MOI and virus
progeny production was determined 24 h p.i. Values represent the mean and
standard deviation of triplicates and are representative of two independent
experiments. The values were compared according to Student’s t test (**Pr0.01).Results
Identiﬁcation of CHIKV-OAS3R showing resistance towards OAS3
We were interested to investigate whether CHIKV is able to
subvert the antiviral effect of OAS3. For this, CHIKV-06.049 strain
was repeatedly passaged in induced HeLa.Tet-Off/OAS3 cells
using a previously reported selection procedure (Mertens et al.,
2010). After 10 serial passages and two steps of cloning by
limiting dilution, a single virus clone, hereafter named CHIKV-
OAS3R, was selected for further studies. CHIKV-06.049 was also
serially passaged on wild-type HeLa.Tet-Off cells resulting in a
CHIK-P10 which served as a virus control. The CHIKV-OAS3R
variant exhibited a smaller plaque phenotype than the parental
CHIKV-06.049 or CHIKV-P10 (Suppl. data 1). In HeLa.Tet-Off/OAS3
cells, progeny production was at least 1.5 log10 higher for the
CHIKV-OAS3R variant than for CHIKV-06.049 (Fig. 1A) and CHIKV-
P10 (Fig. 1B) at multiplicities of infection (MOI) from 0.1 to
10 PFU/cell at 24 h post-infection (p.i.) (Fig. 1A). At 1 MOI, there
was no signiﬁcant difference in viral growth between CHIKV-
OAS3R and CHIKV-P10 in wild-type HeLa.Tet-Off cells (Fig. 1B).
These results suggest that CHIKV-OAS3R displays a greater efﬁ-
ciency at replicating in OAS3 expressing cells than CHIKV-06.49
or CHIKV-P10. Interestingly, infection of mosquito cell cultures
with CHIKV-OAS3R showed that it was not attenuated for viral
growth in invertebrate cells (Suppl. data 2). Also, infection ofadult BALB/c mice with CHIKV-OAS3R was similar to what had
been seen with parental virus after inoculation by intraperitoneal
route (data not shown).
Genetic analysis of CHIKV-OAS3R shows mutations in nsP2,
C and E2 genes
Comparative analysis of the complete sequences of CHIKV-
OAS3R and CHIKV-06.049 identiﬁed one synonymous and three
non-synonymous nucleotide changes between the two viruses
(Table 1). The synonymous nucleotide change T8277C was
located in the C gene whereas the three non-synonymous muta-
tions A1016G, C3090T, and G9037A resulted in nsP1-M314V,
nsP2-T470I and E2-E166K substitutions, respectively. Sequencing
of genomic RNA from CHIKV-P10 suggested that the A1016G
mutation resulted from cell culture adaptation (Table 1).
The G9037A mutation was not observed in CHIKV-P10 indicating
that a glutamine-to-lysine change at position E2-166 was not due
to any positive selection towards epithelial cells.
Sequencing of genomic RNA from CHIKV-OAS3R from all ten
passages as well as the two cloning steps showed that the G9037A
mutation arose at P3 where only nucleotide A was observed at
Table 1
Comparitive sequence analysis of CHIKV-06.049, CHIKV-P10 and CHIKV-OAS3R.
Nucleotide Amino acid
Nucleotide position CHIKV-06.049 CHIKV-P10 CHIKV-OAS3R Amino acid position CHIKV-06.049 CHIKV-P10 CHIKV-OAS3R
1016 A G G nsP1/314 Met Val Val
3090 C C T nsP2/470 Thr Thr Ile
8277 T T C Capsid/237 Arg Arg Arg
9037 G G A E2/166 Glu Glu Lys
Nucleotide changes and amino acid substitutions in CHIKV-OAS3R relative to CHIKV-P10 and parental CHIKV-06.049 are listed.
Fig. 2. Appearance of the C3090T, T8277C and G9037A mutations during selection of CHIKV-OAS3R. In (A), appearance of the three mutations by passaging of CHIKV-06.49
on HeLa.Tet-Off/OAS3 cells. In (B), appearance of the G9037A mutation during ﬁve serial passages of two clinical isolates CHIKV-05.115 and CHIKV-06.027 on HeLa.Tet-Off/
OAS3 cells. Wild-type sequence is represented by white ﬂasks, a mixed population of wild-type and mutation is represented by black/white ﬂasks, and replacement of
original sequence by the mutation is represented in black ﬂasks.
Fig. 3. The G9037A mutant shows a lower vRNA copies/PFU ratio. The C3090T and
G9037A mutations were introduced in CHIKV cDNA infectious clone Mauritius
2006 by site-directed mutagenesis. The vRNA copies/PFU ratio was determined for
virus stocks of wild-type and mutant CHIKV by dividing the number of vRNA
copies as measured by qRT-PCR with the number of PFU. Measurements were
performed in triplicates and values represent the mean and standard deviation.
The values were compared according to One-way ANOVA test (*Pr0.05).
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mutations occurred during the stages of cloning by limiting
dilution. To determine whether the G9037A mutation may occur
in other clinical isolates of CHIKV after a limited number of
passages on HeLa.Tet-Off/OAS3 cells, we performed ﬁve passages
of two clinical isolates from La Re´union, CHIKV-05.115 and
CHIKV-06.027, on these cells. Remarkably, the G9037A mutation
was detected as early as P2 for CHIKV-05.115 and P3 for CHIKV-
06.027 (Fig. 2B). Given than a small number of passages of various
CHIKV isolates on human cells expressing OAS3 resulted in the
G9037A mutation, we hypothesized that this nucleotide change
could be important for CHIKV-OAS3R.
The G9037A mutation restores CHIKV replication
in OAS3 expressing cells
To assess the importance of the G9037A mutation in rescue of
viral growth in HeLa.Tet-Off/OAS3 cells, the mutation was intro-
duced into the full-length CHIKV cDNA infectious clone Mauritius
2006. Live virus derived from pCHIKV Mauritius 2006 vector and
clinical isolate CHIKV-06.049 showed similar sensitivity to the
antiviral effect of OAS3 in HeLa cells (data not shown). The
G9037A mutant exhibited a small plaque phenotype in Vero cells
as it had been observed with CHIKV-OAS3R (Suppl. data 1).
Quantitative real-time RT-PCR assay was performed to determine
the viral RNA (vRNA) copies/PFU ratio for wild-type CHIKV and
G9037A mutant (Fig. 3). CHIKV mutants containing the C3090T
mutation with or without G9037A mutation were utilized as
controls. There was an infectivity ratio of about 500 vRNA copies/
PFU for wild-type virus and C3090T mutant whereas a ratio of
200 vRNA copies/PFU was observed with G9037A mutants with or
without C3090T mutation. These results suggest that the G9037A
mutation decreases the virus particles/PFU ratio for CHIKV.
In HeLa.Tet-Off/OAS3 cells infected with wild-type CHIKV or
C3090T mutant at 1 MOI, there was no signiﬁcant difference in
virus progeny production (Fig. 4A). In contrast, there was 1 log10
higher virus progeny production for the G9037A mutants when
compared to wild-type CHIKV indicating that viral growth was
rescued when the nucleotide at position 9037 was mutated.We investigated whether the G9037A mutant restored vRNA
accumulation in HeLa.Tet-Off/OAS3 cells. At 18 h p.i., there was
a 9- to 10-fold difference in the amount of vRNA in cells infected
with G9037A mutant when compared to wild-type CHIKV and
C3090T mutant (Fig. 4B). Thus, CHIKV bearing the G9037A
mutation replicates better in OAS3 expressing HeLa cells.
The replication efﬁciency of the G9037A mutant was further
studied using a molecular clone of CHIKV Mauritius 2006 in
which translation of genomic RNA produced the reporter Renilla
luciferase (ren.Luc) protein (Fig. 5A). This allowed us to monitor
early stages of viral replication as the ren.Luc gene is expressed as
an integrated part of the non-structural polyprotein of CHIKV.
To validate this recombinant CHIKVLuc, ren.Luc activity was
measured at different time points post infection and after differ-
ent virus input. The ren.Luc activity increased with the time of
infection and was dependent on the MOIs (Fig. 5B and C).
Consequently, assays were performed at 1 MOI and ren.Luc
activity was measured at the time point of 6 h p.i. The G9037A
Fig. 4. The G9037A mutation restores viral replication in OAS3 expressing cells.
HeLa.Tet-Off/OAS3 cells were infected with wild-type CHIKV or mutants with the
C3090T and G9037A mutations alone or in combination at 1 MOI. In (A), virus
progeny production was determined at 24 h p.i. In (B), vRNA production was
determined by qRT-PCR at 18 h p.i. and expressed as fold increase relative to wild-
type virus. Values represent the mean and standard deviation of triplicates and are
representative of two independent experiments. The values were compared
according to One-way ANOVA test (*Pr0.05, **Pr0.01).
H. Henrik Gad et al. / Virology 434 (2012) 27–3730and C3090T mutations were introduced into the molecular clone
CHIKVLuc. Compared to the wild-type CHIKVLuc and CHIKVLuc-
C3090T mutant, ren.Luc activity was signiﬁcantly increased in
HeLa.Tet-Off/OAS3 cells infected with CHIKVLuc bearing the
G9037A mutation (Fig. 5D). Overall, our results indicate that the
G9037A mutation restores vRNA accumulation in OAS3 expressing
cells.
The G9037A mutation (E2-E166K) acts on the stage of viral entry
Although the consequences of mutating the nucleotide 9037
on CHIKV replication in HeLa.Tet-Off/OAS3 cells were evident, it
was not known if the improvement was at the stage of viral entry
or post-entry level. To determine this, in vitro transcribed RNA
from pCHIKVLuc or pCHIKVLuc-G9037A vector was transfected into
HeLa.Tet-Off or HeLa.Tet-Off/OAS3 cells and lysate samples col-
lected at 18 h post transfection (Fig. 6). Compared to wild-type
vRNA, there was a comparable reduction of ren.Luc activity in
HeLa.Tet-Off/OAS3 cells transfected with vRNA mutated at posi-
tion 9037. Because vRNA replication in the mutant sample was
not rescued, it seems unlikely that the effect of mutating nucleo-
tide 9037 was at post-entry level. Alphaviruses enters cells
through receptor-mediated endocytosis and binding to host
receptors is primarily mediated by the E2 protein (Kielian et al.,
2010). Viral entry assays were performed to determine whether
the G9037A mutation resulting in E2-E116K substitution has aneffect on time course of CHIKV penetration after binding to
host cells (Fig. 7). To examine the internalization of CHIKV into
HeLa cells, CHIKVLuc-G9037A mutant or wild-type CHIKVLuc was
allowed to bind to the cell surface at 4 1C followed by a shift of
temperature to 37 1C. At different time points after the shift of
temperature, cells were extensively washed and then incubated
with highly neutralizing antibodies against CHIKV to prevent
endocytosis of virus particles bound on the cell surface. Ren.Luc
activity was determined 6 h after the shift of temperature and
each time point post-addition of CHIKV antibody was expressed
as percentage of the time point 90 min (Fig. 7). For wild-type
CHIKVLuc the percentage of ren.Luc activity increased moderately
to reach approximately 20% at the time point 60 min. In contrast,
the level of ren.Luc activity for the CHIKVLuc-G9037A mutant
increased more rapidly and reached 30% at the time point 45 min.
Thus, CHIKV with a lysine at position E2-166 showed a greater
efﬁciency of replication after initial binding than did CHIKV with a
glutamine at the same position (Fig. 7). Overall, our results
indicate that E2-E166K substitution acts on the stage of viral
entry in human epithelial cells.
The E2-E166K substitution improves CHIKV replication
in human myoblasts
Given that G9037A mutation was still detected after ﬁve
passages of CHIKV-OAS3R in wild-type HeLa cells (data not shown),
we were interested to investigate whether the E2-E166K substitu-
tion improved CHIKV replication in human epithelial cells. Fluor-
escence analysis of HeLa cell monolayers infected with CHIKV
expressing VisGreen GFP (CHIKVGFP) at very low MOI (one virus
particle per cell as determined by qRT-PCR) showed that the
CHIKVGFP-G9037A mutant replicated better than wild-type
CHIKVGFP (Fig. 8A). Compared to C3090T mutant and wild-type
CHIKV, there was a signiﬁcant increase in virus progeny production
associated to vRNA accumulation in HeLa cells infected with
G9037A mutant (Fig. 8B and C). Also, the CHIKVLuc-G9037A mutant
exhibited about 8- to 9-fold increase in ren.Luc activity at 6 h p.i.
(Fig. 8D). These results indicate that a glutamine-to-lysine change
at position E2-166 improves viral growth in human epithelial cells
regardless of OAS3.
CHIKV has been shown to infect muscle satellite cells in vivo
(Ozden et al., 2007). To assess the capacity of the E2 mutant to
grow in LHCN-M2 cells which replicate CHIKV in vitro (Ozden
et al., 2007, 2008; Zhu et al., 2007), infected LHCN-M2 cells were
immunostained with antibodies directed against dsRNA or CHIKV
E2 protein at 18 h p.i. (Fig. 9). In mock-infected cells, no dsRNA or
CHIKV E2 protein was detectable. In contrast, dsRNA accumulated
in cytoplasmic foci in LHCN-M2 cells infected with CHIKV.
Interestingly, the ﬂuorescence intensity of both E2 and dsRNA
molecules was more pronounced in myoblasts infected by the
G9037A mutant when compared to wild-type virus. These results
suggest that replication of CHIKV bearing the E2-E166K substitu-
tion was improved in human myoblast cells. To determine this,
LHCN-M2 cells were infected with CHIKVLuc-G9037A mutant and
ren.Luc activity was analysed at 6 h p.i. (Fig. 10). Compared to
wild-type CHIKVLuc, CHIKVLuc-G9037A mutant showed an 8- to
10-fold increase in ren.Luc activity. Thus, a CHIKV with a lysine at
position E2-166 exhibits higher efﬁciency of replication in LHCN-
M2 cells as it had been observed in HeLa cells.
To determine whether the greater capacity of the CHIKVLuc-
G9037A mutant to grow in LHCN-M2 cells leads to a more
pronounced cell death, these cells were infected with both viruses
and cell viability was measured at 24 and 48 h p.i. by a colori-
metric MTT assay (Fig. 11A). At 48 h p.i., cell viability signiﬁcantly
differed between the two viruses with a cell survival of 21% and
33%, respectively, for G9037A mutant and wild-type CHIKV as
Fig. 5. Molecular clone of CHIKV Mauritius 2006 bearing reporter Renilla luciferase gene. In (A), schematic representation of CHIKVLuc cDNA infectious clone. The ren.Luc
gene was inserted between nsP3 and nsP4. The sequences of the two nsP2 protease cleavage sites ﬂanking the ren.Luc gene are shown and the cleavage sites themselves
are indicated by k. The ren.Luc gene is followed by a stop codon which naturally exists in CHIKV between nsP3 and nP4. Read-through of the stop codon occurs 10–20% of
the time during translation in order to produce the full-length non-structural polyprotein. In (B), HeLa.Tet-Off cells were infected with CHIKVLuc at 1 MOI and ren.Luc
activity was measured at different time points p.i. In (C), HeLa.Tet-Off cells were infected with CHIKVLuc at different MOIs and ren.Luc activity was measured at 6 h p.i. and
expressed as fold increase relative to background activity. In (D), HeLa.Tet-Off/OAS3 cells were infected with wild-type CHIKV or mutants with the C3090T and G9037A
mutations alone or in combination at 1 MOI and ren.Luc activity was measured at 6 h p.i. and expressed as fold increase relative to wild-type virus. Values represent the
mean and standard deviation of triplicates and are representative of two independent experiments. The values were compared according to One-way ANOVA test
(*Pr0.05, **Pr0.01).
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more pronounced when E2 was mutated.
By TUNEL assay, we observed that the G9037A mutant was
more efﬁcient at triggering apoptosis pathways in infected LHCN-
M2 cells when compared with wild-type CHIKV (Fig. 11B). Earlier
studies have linked apoptosis and cellular stress with PKR
activation and translational shut-off following alphavirus infec-
tion (Venticinque and Meruelo, 2010). Given that the G9037A
mutant was a potent inducer of apoptosis, we decided to compare
activation of PKR in response to CHIKV infection. LHCN-M2 cells
were infected with G9037A mutant or wild-type CHIKV and lysate
samples were analyzed by immunoblot assay at 24 h p.i. Using an
antibody directed against PKR, we detected a strong induction of
PKR expression in cells transfected with poly(I) poly(C) or treated
with IFN-a as compared with non-treated cells (Fig. 12). In
contrast, no marked difference in PKR expression was observedbetween infected cells and non-treated cells. Phosphorylation of
PKR was detected by immunoblotting with an antibody directed
against PKR phosphorylated on Thr-446 (Fig. 12). As a positive
control, phosphorylation of PKR was clearly evident in cells
transfected with poly(I) poly(C) whereas no activation of PKR
was observed in non-treated cells. Infection of cells with CHIKV
resulted in a robust phosphorylation of PKR. Compared with wild-
type CHIKV, the G9037A mutant resulted in a 2- to 3-fold higher
level of phosphorylated PKR. Because activated PKR can phos-
phorylate eIF2a, we assessed whether eIF2a is phosphorylated
following CHIKV infection. Immunoblot analysis using antibody
directed against eIF2a phosphorylated on Ser-51 showed that
transfection of myoblasts with poly(I) poly(C) resulted in phos-
phorylation of eIF2a whereas a weak signal was detected in non-
treated cells (Fig. 12). Following infection, we observed that
the G9037A mutant resulted in a 3- to 4-fold increase in
Fig. 6. Transfection of OAS3 expressing cells with vRNA mutated at nucleotide
9037. HeLa.Tet-Off or HeLa.Tet-Off.OAS3 cells were transfected with in vitro
transcribed RNA from the pCHIKVLuc or pCHIKVLuc-G9037A vector. At 18 h post
transfection, cells were lysed and lysates samples were analyzed for ren.Luc
activity. Values represent the mean and standard deviation of triplicates.
Fig. 7. Comparison of viral entry between CHIKVLuc-G9037A mutant and wild-
type CHIKVLuc in HeLa cells. CHIKVLuc and CHIKVLuc-G9037A mutant were allowed
to bind to the cell surface at 4 1C followed by a shift of temperature to 37 1C. At
different time points after the shift of temperature, the inoculum was removed
and cells were incubated with mouse neutralizing anti-CHIKV antibodies at 37 1C
for 6 h. Ren.Luc activity was expressed as percentage where 90 min post-addition
of neutralizing antibodies is set to a hundred percent. Values represent the mean
and standard deviation of triplicates.
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This suggested that activation of the PKR pathway associated to
phosphorylation of eIF2a was affected by the E2-E166K substitu-
tion in human myoblast cells.Discussion
The fact that CHIKV strains are highly sensitive to the antiviral
activity of the large form of human OAS, OAS3, opens the question
whether CHIKV may develop strategies to circumvent the anti-
viral activity of OAS3 in human cells (Brehin et al., 2009). In the
present study, a method previously used for selection of virus
variants showing resistance to OAS (Mertens et al., 2010) was
successfully applied for generation of OAS3-resistant CHIKV using
clinical isolates from the La Re´union epidemic in 2006. By this
approach, we identiﬁed position E2-166 as a key determinantinvolved in the resistance of CHIKV towards OAS3. We showed
that a glutamine-to-lysine change at position E-1662 efﬁciently
rescued CHIKV replication in OAS3-expressing cells. The ability of
CHIKV with a lysine at position E2-166 to productively infect
OAS3-expressing human epithelial cells could be explained by an
enhancement of virus replication rather than a direct antagonism
of OAS3-mediated antiviral activity. Besides OAS3, several other
ISGs including ISG15, ISG20, P56, ZAP and Viperin are known to
exert antiviral activity against alphaviruses (Lenschow et al.,
2007; MacDonald et al., 2007; Werneke et al., 2011; Zhang
et al., 2007). We have undertaken experiments to assess whether
a lysine at position E2-166 alters the sensitivity of CHIKV to
various ISGs including ZAP.
Coffey et al. (2011) reported that CHIKV population with
reduced genetic diversity is less capable of subverting immune
responses. Consistent with this notion, it was reported that pre-
existing CHIKV quasi-species are likely a source of antibody-
escape mutants during the selection process (Lee et al., 2011).
Based on sequencing chromatograms, by passage 3 on OAS3-
expressing cells, we found that lysine was the only amino acid
present at position E2-166 in CHIKV derived from all clinical
isolates used for this study. This substitution was not observed
after serial passage of CHIKV on wild-type cells. Thus, it is
tempting to speculate that CHIKV variants bearing a lysine at
position E2-166 existed as quasi-species in the original clinical
isolates rather than arising de novo. Moreover, CHIKV with a
lysine at position E2-166 was not impaired for viral growth in
mosquito cells in vitro. Although a lysine at position E2-166 has
not yet been reported in already sequenced isolates of CHIKV
throughout the world, there is an urgent need to study the
pathogenicity of this CHIKV variant in live mosquito vector as
well as mammals such as non-human primates and mice
(Couderc et al., 2008; Dubrulle et al., 2009; Labadie et al., 2010;
Ziegler et al., 2008). Our preliminary data show that replication of
CHIKV with a lysine at position E2-166 was not impaired in
adult mice.
Previous reports showed that CHIKV targets human muscle
satellite cells and viral replication in myoblasts might be related
to the pathogenesis of Chikungunya disease in humans (Ozden
et al., 2007). Given that a CHIKV variant with a lysine at position
E2-166 displays improved replication in human epithelial cells,
viral growth was studied in immortalized myoblasts in culture.
Again, we found that a glutamine-to-lysine change at position
E2-166 results in an improvement of CHIKV replication in human
myoblasts. We can therefore conclude that a lysine at position E2-
166 shows a remarkable propensity to promote CHIKV replication
in human cells of different tissue origin. Alphavirus life cycle
involves the production of viral dsRNA that activate PKR by
autophosphorylation (White et al., 2011). The growth of CHIKV
with a lysine at position E2-166 was associated with a more
robust phosphorylation of PKR and eIF2a in human myoblasts
when compared with CHIKV with a glutamine at position E2-166.
Classically, activated PKR phosphorylates eIF2a that, in turn,
becomes inactive leading to a shut-off of cellular mRNA transla-
tion. Whereas cellular mRNA translation is severely hampered,
alphaviruses has developed strategies to elude general translation
arrest due to the inactivation of eIF2a (McInerney et al., 2005;
Ventoso et al., 2006). Phosphorylation of eIF2a may be mediated
by various kinases that are activated by cellular stress due to viral
infection. It is likely that the marked capacity of CHIKV with a
lysine at position E2-166 to trigger apoptotic cell death was a
direct consequence of a more pronounced virus-induced stress.
Given that CHIKV may infect human cells by hiding in apoptotic
blubs (Krejbich-Trotot et al., 2011), we cannot rule out that more
severe apoptosis triggered by a CHIKV bearing a lysine at position
E2-166 may inﬂuence the outcome of CHIKV infection.
Fig. 8. The G9037A mutation promotes viral growth in human epithelial cells. In (A), HeLa cells were infected with CHIKVGFP-G9037A mutant or wild-type CHIKVGFP at a
very low MOI (one virus particle per cell as determined by qRT-PCR) or mock-infected (no virus). At 24 h p.i., cells were ﬁxed and labeled with CyTM3-conjugated mouse
monoclonal 3E4 antibody against CHIKV E2 (Red color). Nuclei were stained with DAPI (Blue color). The GFP VisGreen (Green color), the E2 associated to plasma
membrane, and nuclei were visualized by ﬂuorescence microscopy. The pictures are representative of four independent assays. In (B), virus progeny production was
determined at 24 h p.i. In B, HeLa.Tet-Off cells were infected with wild-type CHIKV or mutants with the C3090T and G9037A mutations alone or in combination at 1 MOI.
In (C), vRNA production was determined by qRT-PCR at 18 h p.i. and expressed as fold increase relative to wild-type virus. In (D), ren.Luc activity was measured at 6 h p.i.
and expressed as fold increase relative to wild-type CHIKV. Values represent the mean and standard deviation of triplicates and are representative of two independent
experiments. The values were compared according to One-way ANOVA test (*Pr0.05, **Pr0.01). (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
Fig. 9. Replication of the G9037Amutant in humanmyoblast cells. LHCN-M2 cells were infected with the G9037Amutant or wild-type CHIKV at 1 MOI or mock-infected (no virus).
At 18 h p.i., cells were ﬁxed and labeled with AlexaFluor488 mouse monoclonal 3E4 antibody against CHIKV E2 (Green color) and J2-1101 antibody against RNA (Red color) whereas
nuclei were stained with DAPI (Blue color). Intracellular E2, dsRNA and nuclei were visualized by immunoﬂuorescence microscopy. (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version of this article.)
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H. Henrik Gad et al. / Virology 434 (2012) 27–3734In conclusion, we have shown that CHIKV can circumvent the
antiviral activity of OAS3 through a single point mutation at
nucleotide position 9037 leading to a glutamine-to-lysine change
at position E2-166. Based on the crystal structure data on the
CHIKV E3-E2-E1 complex, the E2-166 residue maps within the
acid-sensitive region of E2 in close vicinity to both E1 and E3
(Suppl. data 3) (Voss et al., 2010). We observed that CHIKV with
lysine at position E2-166 exhibits a lower vRNA copies/PFU ratio
when compared to CHIKV with a glutamine at the same position.
The greater infectivity of virus particles could contribute to
differences in the time course of virus replication. Viral entry
assays showed that a glutamine-to-lysine change at position
E2-166 leads to a CHIKV that enters the replication pathway
more efﬁciently. Therefore, it is urgent to understand how the
glutamine-to-lysine change at position E2-166 affects interac-
tions of CHIKV at the level of viral entry. Improved knowledge ofFig. 10. The G9037A mutation enhances viral replication in myoblasts infected
with CHIKV. LHCN-M2 cells were infected with wild-type CHIKVLuc or CHIKVLuc-
G9037A mutant at 1 MOI and ren.Luc activity was measured at 6 h p.i. and
expressed as fold increase relative to wild-type CHIKV. Values represent the mean
and standard deviation of triplicates and are representative of two independent
experiments. The values were compared according to Student’s t test (**Pr0.01).
Fig. 11. The G9037A mutant is a potent inducer of apoptosis in myoblasts. In (A), LHCN
viability was measured by MTT assay at 24 and 48 h p.i. and expressed as percentage
represent the mean and standard deviation. The values were compared according to Stu
color) and labeled with CyTM3-conjugated mouse monoclonal 3E4 antibody against CHIK
were visualized by immunoﬂuorescence microscopy. (For interpretation of the referencesthe mechanism by which a lysine at position E2-166 enhances
viral replication will broaden our understanding on viral deter-
minants that contribute to the pathogenic properties of CHIKV.Fig. 12. Activation of the PKR pathway in myoblasts infected with the G9037A
mutant. LHCN-M2 cells were infected with G9037A mutant or wild-type CHIKV at
1 MOI, transfected with poly(I) poly(C) (1 mg) or treated with huIFN-a (100 IU/ml).
At 24 h p.i./post treatment, lysate samples were analyzed by western blotting using
speciﬁc antibodies against the indicated proteins. Quantiﬁcation of bands revealed a
2- to 3-fold increase of phosphorylated PKR and a 3- to 4-fold increase of
phosphorylation eIF2a for the G9037A mutant as compared to wild-type CHIKV.
-M2 cells were infected with wild-type CHIKV or G9037A mutant at 1 MOI and cell
of mock-infected cells. Experiments were performed in quadruplicates and values
dent’s t test (**Pr0.01). In (B), apoptotic cells were stained by TUNEL assay (Green
V E2 (Red color) at 24 h p.i. Nuclei were stained with DAPI (Blue color). Labeled cells
to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Reagents and antibodies
Recombinant human IFN-aA/D was purchased from BioSource.
Poly(I) poly(C) was purchased from GE Healthcare. Antibodies
against GAPDH (SC-51906) and PKR (SC-707) were purchased
from Santa Cruz Biotechnology, Inc. Antibodies against eIF2a
(#9722) and Phospho- eIF2a (Ser51) (#9721) were purchased
from Cell Signaling Technologys. Antibody against Phospho-PKR
(Thr446) (#1120-1) was purchased from Epitomicss. Antibody
against dsRNA (J2-1101) was purchased from English and Scien-
tiﬁc Consulting.
Cell lines and viruses
The HeLa.Tet-Off and HeLa.Tet-Off/OAS3 cell lines were estab-
lished as previously described (Brehin et al., 2009). HeLa.Tet-Off
cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (DMEM/
10% FBS), 200 mg/ml G418, 100 U/ml penicillin and 100 mg/ml
streptomycin. HeLa.Tet-Off/OAS3 cells were cultured in DMEM/
10% FBS, 200 mg/ml G418, 100 mg/ml hygromycin, 2 mg/ml tetra-
cycline, 100 U/ml penicillin and 100 mg/ml streptomycin. Vero
cells were cultured in DMEM supplemented with 10% FBS,
100 U/ml penicillin and 100 mg/ml streptomycin. LHCN-M2 cells
were cultured in DMEM with 20% Medium 199, 20% FBS, 100 U/ml
penicillin and 100 mg/ml streptomycin (Zhu et al., 2007).
All incubations were performed at 37 1C in a 5% CO2 gassed
incubator.
The CHIKV-05.115, 06.027 and 06.049 strains were iso-
lated from three different patients during the 2005–2006 out-
break of Chikungunya fever on La Re´union island and have been
passaged twice on C6/36 mosquito cells (Schuffenecker et al.,
2006). Virus stocks were grown on Vero cells in DMEM/2% FBS
and titrated by plaque assay on these cells as previously described
(Brehin et al., 2008).
Selection of OAS3-resistant CHIKV variants
CHIKV was serially passaged on induced HeLa.Tet-Off7OAS3
cells in 25-cm2 tissue culture ﬂasks. For the ﬁrst passage, cells
were infected at a MOI of 0.2 and virus supernatant was harvested
after 48 h. For subsequent passages, 100 ml of virus supernatant
was used to infect cells for the next passage and so on. After 10
serial passages and two steps of cloning by limiting dilution, a
single virus clone, CHIKV-OAS3R, was selected based on its
capacity to grow in HeLa.Tet-Off/OAS3 cells. As a control, serial
passage of CHIKV on HeLa.Tet-Off cells was performed except that
only 10 ml of virus supernatant was used to initiate each passage.
Sequencing of genomic RNA from CHIKV
Genomic RNA was extracted from viral supernatants using the
NucleoSpin RNA II Kit (Macherey-Nagel) and RT-PCR was per-
formed using SuperScript One-Step RT-PCR with platinum Taq
(Invitrogen) with primers targeting the entire viral genome
(Schuffenecker et al., 2006). RT-PCR fragments were puriﬁed by
ultraﬁltration. Sequencing reactions were performed using the Big
Dye Terminator v1.1 cycle sequencing kit (Applied Biosystems).
Sequence chromatograms from both strands were obtained on
automated sequence analyzer ABI3730XL (Applied Biosystems).
For sequence analysis, contig assemblies and sequence align-
ments were performed using program BioNumerics version 6.6
(Applied-Maths).Real-time RT-PCR
RNA was extracted from infected cells or viral particles using the
NucleoSpin RNA II kit (Machery-Nagel) according to manufacturer’s
recommended procedure. RT-qPCR analysis of vRNA was performed
on a DNA Engine Opticons 2 System (Bio-Rad Laboratories, Inc.)
using the QuantiTects SYBRs Green RT-PCR Kit (QIAGEN GmbH).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA was
used as reference gene. The following primers were used:CHIKV 50 CACCGCCGCAACTACCG
CHIKV 30 GATTGGTGACCGCGGCA
GAPDH 50 AGTGGGGCGATGCTGGC
GAPDH 30 ACCTTGGCCAGGGGTGCRelative levels of vRNA production were compared using the
ddCT method (Livak and Schmittgen, 2001). For the quantiﬁcation
of vRNA copies, in vitro RNA transcript from full-length cDNA
infectious clone of CHIKV Mauritius 2006 was used to build a
standard curve.
Site-directed mutagenesis of CHIKV infectious clone
The CHIKV infectious clone, Mauritius 2006, was based on
CHIKV isolate BNI-CHIKV 899 (GenBank accession number
FJ959103) from a German tourist who visited Mauritius during
the outbreak in 2006. The full-length cDNA was cloned into the
low copy vector pSMART-LCK using the Clone SMART Blunt
cloning kit (Lucigen) (C. Drosten and B.M. Ku¨mmerer, unpub-
lished data). The resulting pCHIKV Mauritius 2006 vector contains
a T7 promoter sequence at the 50 end of the viral cDNA and a Not I
linearization sites at the 30 end. RNA was transcribed in vitro from
linearized pCHIKV Mauritius 2006 vector using the mMESSAGE
mMACHINEs Kit (Ambion) and electroporated into Vero cells.
Viral supernatants were collected after 48 h (ﬁrst passage or P1)
and used to infect Vero cells in order to grow ﬁnal virus stocks for
experiments (second passage or P2). Individual mutant viruses
were generated by site-directed mutagenesis of CHIKV infectious
clones using the QuikChanges II XL Site-Directed Mutagenesis Kit
(Agilent Technologies).
Construction of CHIKV infectious clones expressing Renilla luciferase
or VisGreen GFP
For the construction of recombinant CHIKV expressing Renilla
luciferase or VisGreen GFP as a reporter, we used a strategy
similar to what has previously been done with Semliki Forest
virus (Tamberg et al., 2007). Modiﬁcations that reduce the
percentage of GþC content from 60% to 49% in VisGreen GFP
(GenBank accession number ABR26680) were done on the origi-
nal sequence (Teerawanichpan et al., 2007) using a synthetic
gene. Renilla luciferase or VisGreen GFP is expressed as an integral
part of the non-structural polyprotein precursor and is naturally
excised by the viral protease nsP2. Brieﬂy, Renilla luciferase or
VisGreen GFP gene was inserted in-frame between nsP3 and nsP4
in the non-structural polyprotein precursor and ﬂanked on both
sides by nsP2 protease cleavage sites. For the construction of
recombinant CHIKV, a cassette gene coding for the C-terminal
region of nsP3 followed in-frame by the nsP1/2 cleavage site, a
unique Spe I restriction site, the Opal codon of nsP3, the nsP3/4
cleavage site, and the N-terminal region of nsP4 gene were
inserted between the SanD I and Age I restriction sites of CHIKV
cDNA infectious clone. The Renilla luciferase or GFP VisGreen gene
was inserted in-frame within the Spe I restriction site and
the resulting plasmids were named pCHIKVLuc and pCHIKVGFP,
H. Henrik Gad et al. / Virology 434 (2012) 27–3736respectively. RNA was transcribed in vitro from linearized pCHIKLuc
or pCHIKVGFP plasmid using the mMESSAGE mMACHINE
s Kit
(Ambion) and electroporated into Vero cells resulting in production
of live CHIKVLuc and CHIKVGFP viruses. Viral supernatants were
collected after 48 h (ﬁrst passage or P1) and used to infect Vero
cells in order to grow ﬁnal virus stocks for experiments (second
passage or P2).Renilla luciferase assay
Cells were infected with CHIKVLuc and lysed with Passive Lysis
Buffer (Promega). After clariﬁcation for 10 min at 13,000 g,
Renilla luciferase (ren.Luc) activity was measured on a Centro LB
960 (Berthold Technologies, GmbH) luminometer by mixing 25 ml
Dual-Glos Stop & Glos Substrate (Promega) with 100 ml cell
lysate sample and measuring luminescence for 10 s.Viral RNA transfection of human cells
RNA was in vitro transcribed from the pCHIKVLuc vector or
mutants and transfected into HeLa.Tet-Off or Hela.Tet-Off/OAS3
cells using TurboFect transfection reagent according to the
manufacturer’s recommendations (Fermentas Molecular Biology).
Brieﬂy, HeLa cell monolayers in 12-well tissue culture plates
(3105 cells/well) were transfected with 2 mg of RNA in a total
volume of 200 ml transfection reagent. At 18 h post transfection,
transfected cells were lysed and lysates samples were analyzed
for ren.Luc activity.Viral entry assay
Conﬂuent HeLa cell monolayers in 12-well tissue culture
plates were cooled and washed three times in cold DMEM
supplemented with buffered 0.2% bovine serum albumin (BSA).
Cells were incubated with CHIKV at a MOI of 1 in 0.5 ml of cold
DMEM supplemented with BSA at 4 1C. After 1 h of incubation at
4 1C on a rocking platform, cells were moved to 37 1C. Cells were
washed three times with DMEM supplemented with 2% FBS after
5, 15, 30, 45, 60 and 90 min at 37 1C and incubated with 0.5 ml
DMEM supplemented with 2% FBS and 5 ml neutralizing antibo-
dies against CHIKV (PRNT90¼350) (Brehin et al., 2008) in order to
neutralize bound but not endocytosed virus particles. At 6 h after
shift of temperature, cells were lysed and luciferase activity was
measured as described above.Western blot analysis
Cells were lysed with CelLyticTMM Cell Lysis Reagent (Sigma-
Aldrich) containing a mixture of protease inhibitor (Roche
Applied Science). Samples were separated on a 4–12% Bis-Tris
Gel (Invitrogen) and afterwards blotted onto a PVDF membrane
(Invitrogen). Following the blotting procedure, the membrane
was blocked in 10% skim milk dissolved in TPBS for 2 h at room
temperature. Next, the membrane was incubated O.N. at 4 1C with
the primary antibody diluted in TPBS. The membrane was washed
at least ﬁve times for 5 min with TPBS before incubation with
secondary antibody for 2 h at RT. Finally, the membrane was
washed at least ﬁve times for 5 min with TPBS and then revealed
using ECL Plus Western Blotting Detection System. Images were
captured on a G:BOX Chemi (Syngene) and bands were quantiﬁed
with GeneTools version 4.00 (Syngene) and normalized to GAPDH
expression levels.Immunoﬂuorescence analysis
Cells infected with CHIKV or CHIKVGFP were ﬁxed with 3.2%
paraformaldehyde in PBS for 20 min and permeabilized or not
with 0.1% Triton X-100 for 4 min. Cells were stained with
antibodies in PBS at 37 1C for 30 min. CHIKV E2 protein was
detected using AlexaFluor488-conjugated mouse monoclonal 3E4
antibody (Brehin et al., 2008). Intracellular dsRNA was detected
using J2-1101 antibody (English & Scientiﬁc Consulting) and
CyTM3-conjugated AfﬁnityPure Donkey Anti-Mouse IgG (Jackson
ImmunoResearch Laboratories, Inc.). The samples were mounted
in Prolongs Gold antifade reagent with DAPI (Invitrogen) and
ﬂuorescence images were taken with an AxioObserver or Axiovert
200M inverted microscopes (Zeiss). The same microscope settings
and exposure times were used within each set of experiments.
Pictures were obtained using the AxioVision 4.5 software.
Cell death analysis
For analysis of CHIKV-mediated cell death, growth medium
was removed from infected cells and replaced by 1 mg ml1
3-(4,5-dimethylthiazol-2-yl)-2,-diphenyltetrazolium bromide
(MTT) in medium and cells were incubated for an additional
3 h. Medium was then removed and the MTT dissolved in
dimethyl sulfoxide before absorption was measured at 595 nm
with background subtracted at 650 nm as a measure of cell
viability. Apoptosis triggered by CHIKV was visualized in situ
using the terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) method. Brieﬂy, infected cells were ﬁxed with
3.2% paraformaldehyde in PBS for 20 min and permeabilized with
0.1% Triton X-100 in PBS for 2 min. Apoptotic cells were stained
using the In Situ Cell Death Detection Kit, Fluorescein (Roche)
according to manufacturer’s recommended procedure.
Statistical analysis
All statistical analyses were performed using GraphPad Prism
version 5.04 (GraphPad Software).Acknowledgments
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